Undergoing both RRM and RRSO was most cost-effective for BRCA1 (RRM at age 30 years; RRSO at age 35 years), BRCA2 (RRM at age 35 years; RRSO at age 40 years), and PALB2 (RRM at age 40 years; RRSO at age 45 years), potentially preventing 464 to 923 OC and BC cases and 130 to 302 deaths per 1000 PV carriers. This evidence concerns the gene BRCA1 and breast cancer.